LINE250117C65000
- 0.40
- 0.000.00%
Lineage Newsroom
Truist Financial Maintains Lineage(LINE.US) With Buy Rating, Cuts Target Price to $65
Truist Financial Reaffirms Their Buy Rating on Lineage, Inc. (LINE)
Lineage Is Maintained at Buy by Goldman Sachs
Lineage Analyst Ratings
Goldman Sachs Maintains Buy on Lineage, Lowers Price Target to $77
Goldman Sachs Maintains Lineage(LINE.US) With Buy Rating, Cuts Target Price to $77
Evercore Maintains Lineage(LINE.US) With Hold Rating, Maintains Target Price $71
Evercore Maintains Lineage(LINE.US) With Hold Rating, Cuts Target Price to $71
Balanced Hold Recommendation for Lineage, Inc. Amid Market Concerns and Strategic Adjustments
Morgan Stanley Maintains Lineage(LINE.US) With Buy Rating, Cuts Target Price to $80
Morgan Stanley Keeps Their Buy Rating on Lineage, Inc. (LINE)
BNP Paribas Initiates Lineage(LINE.US) With Hold Rating, Announces Target Price $61
Lineage Cell Therapeutics Price Target Cut to $3.00/Share From $5.00 by Maxim Group
Lineage Cell Therapeutics Is Maintained at Buy by Maxim Group
Lineage Is Maintained at Neutral by Mizuho
Mizuho Securities Maintains Lineage(LINE.US) With Hold Rating, Cuts Target Price to $67
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target
Lineage Cell Therapeutics Analyst Ratings
Morgan Stanley Maintains Lineage(LINE.US) With Buy Rating, Maintains Target Price $95
Morgan Stanley Maintains Lineage(LINE.US) With Buy Rating, Cuts Target Price to $95